Prospects for cannabinoid therapies in basal ganglia disorders.

Author(s): Fernández-Ruiz J, Moreno-Martet M, Rodríguez-Cueto C, Palomo-Garo C, Gómez-Cañas M, Valdeolivas S, Guaza C, Romero J, Guzmán M, Mechoulam R, Ramos JA.

Departamento de Bioquímica y Biología Molecular III, Instituto Universitario de Investigación en Neuroquímica, Facultad de Medicina, Universidad Complutense, Madrid, Spain. [email protected]

Subject: Parkinson's Disease View the study

Abstract:

Cannabinoids are promising medicines to slow down disease progression in neurodegenerative disorders including Parkinson's disease (PD) and Huntington's disease (HD), two of the most important disorders affecting the basal ganglia. Two pharmacological profiles have been proposed for cannabinoids being effective in these disorders. On the one hand, cannabinoids like Δ(9) -tetrahydrocannabinol or cannabidiol protect nigral or striatal neurons in experimental models of both disorders, in which oxidative injury is a prominent cytotoxic mechanism.

Source: British Journal of Pharmacology
Share Tweet

More medical studies related to Parkinson's Disease:

View all medical studies >>

Subscribe for daily cannabis news, announcements, and business insights.

курс метана

220km.net/

www.viagraon.com